MedTrace Logo

Study on the Clinical Efficacy of Teclistamab

NCT06477783 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-03-12

No results posted yet for this study

Summary

The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA/CD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.

Conditions

Interventions

DRUG

Teclistamab

Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.

Sponsors & Collaborators

  • Janssen Pharmaceutica

    collaborator INDUSTRY

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Michel Delforge, MD, PhD · UZ Leuven Gasthuisberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477783 on ClinicalTrials.gov